For security reasons and to continue to access your member area, we thank you for validating your member account by clicking on the following link:
I validate my member account
You will receive an email at the address indicated when you created your account.

Then click on the link in the email. You will then be able to access your member account again.

If you have not received this email,
contact us

8 characters minimum

1 uppercase

1 lowercase

1 digit

1 special character

Different from your nickname

Both passwords are the same

Benefit from additional features and services free of charge.
become a member

New to Boursorama?
become a member

(AOF) – Quantum Genomics jumped 12.7% to 5.815 euros for its resumption of quotation. The title of biotech was suspended from the opening last Friday at 5.16 euros pending scientific results unveiled a few hours later at the ESC (European Society of Cardiology) congress.

Results from Quorum, the Phase IIb Study Show that Firibastat, the treatment from Quantum Genomics, achieves the same benefits as the global gold standard treatment for heart failure (Ramipril) but is the only treatment without the side effect on blood pressure.

According to the biotech, these results completely change its status because after having demonstrated promising results in arterial hypertension (phase IIB study conducted 2 years ago and of which phase III is in progress), its Firibastat treatment confirms with the ‘heart failure.

All of Firibastat’s potential indications thus represent billions of potential annual sales from 2023 and this double indication opens the way to major partnerships with large European or American laboratories in the short term, underlined the biotech.

In a note published at the end of May, Oddo BHF estimated that the results of this Quorum study were not vital for the group but that if these results are positive, the M&A spectrum would be most credible.

The broker had specified that phase III would be too expensive for the group and that a partnership would be necessary to carry out phase III.

In the end, the broker began monitoring the security with an Outperformance opinion and a price target of 12 euros.

Asked by AOF, Jean-Philippe Milon, CEO of Quantum Genomics, confirmed that the treatment was as effective as the reference drug against heart failure (Ramipril), but that he was not hypotensive. It can thus provide patients with hypotension, unlike Ramipril.

Regarding the financing of phase III, the manager is confident in the discussions that will begin with the multinationals. If successful, he discounts, against his molecule, an initial payment, milestone payments and finally royalties on double-digit sales.

Phase I: testing of the molecule on a small scale in humans to assess its safety, tolerance, metabolic and pharmacological properties.

Phase II: safety and efficacy evaluation on several hundred patients to identify side effects.

Phase III: evaluation of the overall benefit / risk ratio in several thousand patients.

At the end of a recent CSIS, the French authorities announced an unprecedented amount of credits (7 billion euros): 1.5 billion for university hospital research, 2 billion for investment in health via bpi France , 1.5 billion in aid for the relocation of industrial projects, and 2 billion to strengthen investment in three sectors of the future (bioproduction, digital medicine, and pandemic preparedness). In addition, the annual growth in drug expenses reimbursed by Medicare will be 2.4%, which should generate growth of at least 0.5% in laboratory turnover,

Above all, the normal drug marketing procedure will be accelerated (up to 500 days saved) if the actual benefit is sufficient.

Acting exclusively as a distribution channel, BOURSORAMA did not participate in any way in its development nor exercised any discretionary power with respect to its selection. The information contained in this analysis has been transcribed “as is”, without any representation or warranty of any kind. The opinions or estimates expressed therein are those of its authors and do not reflect the point of view of BOURSORAMA. Subject to applicable laws, neither the information contained nor the analyzes expressed therein can engage BOURSORAMA’s responsibility. The content of the analysis made available by BOURSORAMA is provided for information only and has no contractual value. It thus constitutes a simple decision aid over which the user retains absolute control.

BOURSORAMA is a credit institution under French law approved by the Prudential Control and Resolution Authority (“ACPR”) and by the Financial Markets Authority (“AMF”) as an investment services provider and under the prudential supervision of the European Central Bank (“ECB”).

In accordance with the regulations in force, BOURSORAMA establishes and maintains operational a conflict of interest management policy and implements administrative and organizational measures to prevent, identify and manage conflict of interest situations with regard to the recommendations of investment broadcast. These rules notably contain provisions relating to personal financial transactions in order to ensure that BOURSORAMA employees are not in a situation of conflict of interest when Boursorama issues investment recommendations.

The reader is informed that BOURSORAMA has no conflict of interest that could affect the objectivity of the analyzes disseminated. As such, the reader is informed that there is no direct link between the analyzes disseminated and the variable remuneration of BOURSORAMA employees. Likewise, there are no financial or capital links between BOURSORAMA and the issuers concerned, apart from the contractual commitments that may govern the provision of the broadcasting service.

It is recalled that the entities of the Societe Generale group, to which BOURSORAMA belongs, may carry out transactions on the financial instruments mentioned in this analysis, hold stakes in the companies issuing these financial instruments, act as market maker, advise , broker, or banker of these instruments, or be represented on the board of directors of these companies. These circumstances can in no way affect the objectivity of the analyzes disseminated by BOURSORAMA.

You must be a member to add a comment.

Already a member ?
Log in

Not a member yet ?
Join for free

Related title :
Quantum Genomics resumes its listing
The value of the day at Paris Quantum Genomics resumes its quotation
Paris opening: stable CAC40, biotechs in sight!
CM – The quotation of Quantum Genomics is again significantly higher after the positive results of …
Quantum Genomics’ listing resumes sharply higher after positive firibastat results

Ref: https://www.boursorama.com